Sarepta Therapeutics (SRPT) option implied volatility elevated
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Evercore on Sarepta (SRPT) Post Stat News Article: 'probably sets up for the adcomm briefing documents and tone to be somewhat more negative'
April 13, 2023 10:39 AM EDTEvercore ISI analyst Gavin Clark-Gartner reiterated an Outperform rating and $149.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "The STAT article from this morning (HERE) is a must-read. To briefly summarize: the market had thought SRPTs... More
